Grazyna Liebérman

2.3k total citations · 1 hit paper
9 papers, 1.7k citations indexed

About

Grazyna Liebérman is a scholar working on Oncology, Statistics and Probability and Computational Theory and Mathematics. According to data from OpenAlex, Grazyna Liebérman has authored 9 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Statistics and Probability and 2 papers in Computational Theory and Mathematics. Recurrent topics in Grazyna Liebérman's work include HER2/EGFR in Cancer Research (3 papers), Statistical Methods in Clinical Trials (3 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). Grazyna Liebérman is often cited by papers focused on HER2/EGFR in Cancer Research (3 papers), Statistical Methods in Clinical Trials (3 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). Grazyna Liebérman collaborates with scholars based in United States, Switzerland and Germany. Grazyna Liebérman's co-authors include Herbert I. Hurwitz, William Novotny, Neal J. Meropol, Emily K. Bergsland, Louis Fehrenbacher, Fairooz F. Kabbinavar, René Bruno, Ludger Banken, Jianfeng Lü and Pamela Klein and has published in prestigious journals such as Journal of Clinical Oncology, Nature Reviews Drug Discovery and Cancer.

In The Last Decade

Grazyna Liebérman

8 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

2002 1.3k citations Fairooz F. Kabbinavar, Herbert I. Hurwitz et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Grazyna Liebérman United States	7	1.1k	537	404	268	238	9	1.7k
Chiara Pierantoni Italy	16	809 0.8×	340 0.6×	366 0.9×	145 0.5×	245 1.0×	40	1.3k
Marianne Krahn Canada	3	1.3k 1.2×	247 0.5×	526 1.3×	298 1.1×	198 0.8×	6	1.8k
Taral Patel United States	14	1.4k 1.3×	476 0.9×	1.1k 2.7×	147 0.5×	263 1.1×	38	2.1k
Blair Marshall United States	9	630 0.6×	795 1.5×	514 1.3×	129 0.5×	487 2.0×	10	1.7k
Linnea Chap United States	13	1.0k 1.0×	662 1.2×	367 0.9×	137 0.5×	417 1.8×	28	1.7k
Nobuyuki Mizunuma Japan	23	1.5k 1.4×	506 0.9×	530 1.3×	99 0.4×	367 1.5×	133	2.0k
Wei‐Xiang Qi China	24	1.1k 1.1×	426 0.8×	940 2.3×	186 0.7×	227 1.0×	109	2.1k
Lorenza Landi Italy	22	1.1k 1.1×	611 1.1×	1.0k 2.5×	107 0.4×	423 1.8×	85	1.8k
Séverine Guiu France	24	1.1k 1.1×	399 0.7×	464 1.1×	356 1.3×	751 3.2×	78	1.9k
Carol Peña France	7	765 0.7×	910 1.7×	875 2.2×	166 0.6×	492 2.1×	9	2.3k

Countries citing papers authored by Grazyna Liebérman

Since Specialization

Citations

This map shows the geographic impact of Grazyna Liebérman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grazyna Liebérman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grazyna Liebérman more than expected).

Fields of papers citing papers by Grazyna Liebérman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grazyna Liebérman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grazyna Liebérman. The network helps show where Grazyna Liebérman may publish in the future.

Co-authorship network of co-authors of Grazyna Liebérman

This figure shows the co-authorship network connecting the top 25 collaborators of Grazyna Liebérman. A scholar is included among the top collaborators of Grazyna Liebérman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grazyna Liebérman. Grazyna Liebérman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Ruberg, Stephen J., F. Beckers, Peter K. Honig, et al.. (2023). Application of Bayesian approaches in drug development: starting a virtuous cycle. Nature Reviews Drug Discovery. 22(3). 235–250. 34 indexed citations

2.

Guinn, Daphne, et al.. (2018). Assessing function of electronic health records for real-world data generation. BMJ evidence-based medicine. 24(3). 95–98. 11 indexed citations

3.

Huang, Jie, Asha Das, Hans Ulrich Burger, et al.. (2014). The use of phase 2 interim analysis to expedite drug development decisions. Contemporary Clinical Trials. 38(2). 235–244.

4.

Fridlyand, Jane, Ru‐Fang Yeh, Howard Mackey, et al.. (2013). An industry statistician's perspective on PHC drug development. Contemporary Clinical Trials. 36(2). 624–635. 4 indexed citations

5.

Brufsky, Adam, Barry C. Lembersky, Kathy Schiffman, Grazyna Liebérman, & Virginia Paton. (2005). Hormone Receptor Status Does Not Affect the Clinical Benefit of Trastuzumab Therapy for Patients with Metastatic Breast Cancer. Clinical Breast Cancer. 6(3). 247–252. 43 indexed citations

6.

Bruno, René, Carla Washington, Jianfeng Lü, et al.. (2005). Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 56(4). 361–369. 202 indexed citations

7.

Blackwell, Kimberly, Herbert I. Hurwitz, Grazyna Liebérman, et al.. (2004). Circulating D‐dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer. 101(1). 77–82. 101 indexed citations

8.

Tripathy, Debu, Andrew D. Seidman, Deborah Keefe, et al.. (2004). Effect of Cardiac Dysfunction on Treatment Outcomes in Women Receiving Trastuzumab for HER2-Overexpressing Metastatic Breast Cancer. Clinical Breast Cancer. 5(4). 293–298. 26 indexed citations

9.

Kabbinavar, Fairooz F., Herbert I. Hurwitz, Louis Fehrenbacher, et al.. (2002). Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 21(1). 60–65. 1297 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact